MetaVia Inc Dossier
Qualitative Analysis
Business overview
MetaVia Inc. (formerly NeuroBo Pharmaceuticals, Inc. until its rebranding in late 2024) is a clinical-stage biotechnology company focused on developing and commercializing multi-modal, novel disease-modifying therapies for cardiometabolic diseases. Headquartered in Cambridge, Massachusetts, the company's pipeline is anchored by two primary clinical programs: DA-1726, a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 and glucagon receptor dual agonist for the treatment of obesity, and vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing DA-1726, a novel oxyntomodulin (OXM) analogue functioning as a GLP1R and GCGR dual agonist, through clinical trials for the treatment of obesity.
Expected impact: Demonstrate superior body weight loss and metabolic benefits with optimized titration regimens.
Developing vanoglipel, a novel oral GPR119 agonist, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes.
Expected impact: Provide a well-tolerated oral therapeutic option that reduces liver inflammation and improves glucose regulation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Leverages Syntekabio's proprietary DeepMatcher AI platform to conduct large-scale virtual screening against over 1,700 validated protein targets to identify new therapeutic indications and optimize the profile of vanoglipel (DA-1241).
Terms: Not publicly disclosed.
Provides exclusive global licenses for the development and commercialization of DA-1726 and vanoglipel, with Dong-A ST acting as the sole manufacturer.
Terms: MetaVia incurs direct R&D costs under a Shared Services Agreement, totaling $0.7 million in Q1 2026.